中国临床药理学杂志2024，Vol.40Issue(10)：1409-1413,5.DOI:10.13699/j.cnki.1001-6821.2024.10.004
四烯甲萘醌联合PKP术治疗骨质疏松性椎体压缩骨折患者的临床研究
Clinical trial of menatetrenone combined with PKP in the treatment of patients with osteoporotic vertebral compression fracture
摘要
Abstract
Objective To observe the effect and safety of menatetrenone combined with percutaneous kyphoplasty(PKP)in the treatment of osteoporotic vertebral compression fracture(OVCF).Methods Patients with OVCF were divided into treatment group and control group by random number table method.The control group was treated with PKP and conventional anti-osteoporosis treatment,and the treatment group was treated with menatetrenone 15 mg,tid,on the basis of control group.The two groups were compared on the changes in T value of bone mineral density,Oswestry disability index(ODI)scores,visual analogue scale(VAS)and bone metabolism indicators[osteocalcin(OC),alkaline phosphatase(ALP),C-telopeptide of type Ⅰ collagen(CTX-Ⅰ)and 25-hydroxyvitamin D(25(OH)D)].The incidence rates of refracture and adverse reactions were recorded.Results There were 40 cases in treatment group and 40 cases in control group.After treatment,T values of bone mineral density of lumbar spine(L2-4)in treatment group and control group were-1.79±0.24 and-2.16±0.28;T values of bone mineral density of femoral neck were-1.44±0.16 and-2.01±0.22;T values of bone mineral density of femoral great trochanter were-1.76±0.18 and-1.97±0.23,all with significant difference(all P＜0.05).Three months after operation,ODI scores in treatment group and control group were 34.12±3.56 and 37.67±3.89;six months after operation,ODI scores were 17.85±1.84 and 26.75±2.78;three months after operation,VAS were 2.61±0.28 and 2.84±0.31;six months after operation,VAS were 0.85±0.11 and 1.23±0.16,all with significant difference(all P＜0.05).After treatment,OC levels in treatment group and control group were(9.08±0.95)and(7.64±0.79)μg·L-1;ALP levels were(86.27±8.79)and(91.33±9.25)U·L-1;CTX-Ⅰ levels were(0.21±0.04)and(0.25±0.03)ng·mL-1;the above indexes were significantly different between control group and treatment group(all P＜0.05).The incidence of refracture in treatment group and control group were 10.00％and 2.50％,and the incidence of adverse drug reactions were 10.00％and 17.50％,without statistically significant difference between the two groups(all P＞0.05).Conclusion Menatetrenone combined with PKP can significantly increase bone mineral density of patients with OVCF,improve bone metabolism indicators and reduce lumbar dysfunction and pain,without increasing the risks of refracture and adverse drug reactions.关键词
四烯甲萘醌胶囊/骨质疏松性椎体压缩骨折/经皮球囊扩张椎体后凸成形术/骨代谢Key words
menatetrenone capsules/osteoporotic vertebral compression fracture/percutaneous kyphoplasty/bone me-tabolism分类
医药卫生引用本文复制引用
朱衍,邱雷雨,周筱..四烯甲萘醌联合PKP术治疗骨质疏松性椎体压缩骨折患者的临床研究[J].中国临床药理学杂志,2024,40(10):1409-1413,5.基金项目
浙江省卫生健康科技计划基金资助项目(2022KY1320) （2022KY1320）
